News & stories – CEPI

Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

CEPI partners with Japan's NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine

CEPI will provide funding of up to US$4.8m to support the programme - its first collaboration with Japanese industry.

CEPI invites vaccine developers and manufacturers to join global outbreak response network

Existing vaccine facilities will work to develop, produce, store, and test vaccine candidates in response to new infectious disease outbreaks.

CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

CEPI funding will support trial of UB-612 vaccine candidate as a 'mix-and-match' booster dose.

The Global Pandemic Preparedness Summit: On the road to 100-Day vaccines

Catch-up on the key highlights from the Summit.

Nipah survivors study to advance new vaccines against highly fatal threat

Nipah virus remains one of the deadliest infections known to infect humans, however no vaccines are currently licensed for use.

Global community comes together in support of 100 Days Mission and pledges over $1.5 billion for CEPI’s pandemic-busting plan

The pledges of political and financial support were made by representatives from over 20 countries attending the Global Pandemic Preparedness Summit.

CEPI and DIOSynVax partner in quest to develop broadly protective Betacoronavirus vaccine

This is the latest award under CEPI's $200m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses.

CEPI, UK Government, and Life Sciences Industry unite around 100 Days Mission

100 Days Mission, put forward by the UK Government under its G7 Presidency, and backed by leaders of the G7 and G20, sits at the heart of CEPI’s five-year pandemic preparedness plan.

Japan pledges US$300 million to CEPI’s pandemic preparedness plan

This investment comes at a critical time as the global community strives to end the acute phase of the COVID-19 pandemic and ensure that the world is better prepared to respond to future viral threats.

UK pledges £160 million to CEPI to boost global vaccine development

Funding will support CEPI’s work to cut new vaccine development time to 100 days, which could save millions of lives around the world.

New global vaccine trial launched to evaluate fractional COVID-19 booster shots

CEPI will provide up to US $8.7 million (AU $12.3million) to support the trial, led by the Murdoch Children’s Research Institute (MCRI), Australia, with support from PATH.

Twitter

Follow

Tweets by CEPIvaccines

Media enquiries

Get involved in our cause

Become a partner